The FDA is supposed to be your watchdog. The agency that stands between you and an industry that, left unchecked, will prioritize profits over your safety. So what happens when the watchdog goes to work for the industry it was supposed to be watching?

In this replay of Episode 4, Rob Burgess names names. Three of them. Patrizia Cavazzoni ran the FDA's drug approval center for years — then left for Pfizer as Chief Medical Officer. Peter Marks spent nine years as the FDA's top vaccine regulator — then landed at Eli Lilly as Senior Vice President. Scott Gottlieb ran the entire FDA — then joined Pfizer's board of directors within months of leaving. Rob breaks down what each of them knew, what that knowledge is worth, and why the current law allows all of it.

In this episode:

• How the FDA really works — and why the people running it hold enormous power over the entire pharmaceutical industry
• Patrizia Cavazzoni: eight years at Pfizer, then head of FDA drug approvals, then back to Pfizer as CMO
• Peter Marks: nine years overseeing FDA vaccine approvals, then Senior VP at Eli Lilly — alongside his former deputy
• Scott Gottlieb: ran the whole FDA, joined Pfizer's board within months, and still appears in the press as a "neutral" voice on drug policy
• Why the FDA's funding structure — hundreds of millions in fees paid directly by pharma — creates a conflict of interest baked into the system
• Four specific reforms that would fix it: longer cooling off periods, a ban on board service, mandatory public disclosure, and enforceable recusal

The bottom line: The people running America's drug approval process are one year away from going to work for the companies that want drugs to be expensive. That's industry first, not America First

🔔 New episodes every week — subscribe so you don't miss one.
🌐 Get involved at BustBigPharma.com

One drug. One molecule. 154 patents. That's not a typo — and in this replay episode of Bust Big Pharma, Rob Burgess explains exactly what it means for your pharmacy bill.

Ozempic is the most talked-about drug in America right now. But behind the celebrity endorsements and the glossy TV ads is a story most people never hear: how Novo Nordisk built a legal fortress around a single molecule to keep cheaper competition off the market for years — and how much that delay is worth to them. The answer is $166 billion. Rob breaks down the patent thicketing playbook, why the GLP-1 market changes everything, and how Most Favored Nation pricing is the policy that Big Pharma is actually scared of.

In this episode:

• What a patent thicket is — and why 154 patents around one drug should make every American angry
• The $166 billion Novo Nordisk stands to collect by keeping generics out until 2031
• Why the GLP-1 market is projected to hit $100 billion a year — and what companies will do to protect that
• How real competition would drop prices 50-90% — and why it's being blocked
• Why Americans pay $900-$1,300 a month for drugs that cost a fraction of that overseas
• Most Favored Nation pricing explained — and why Big Pharma fought it so hard

The bottom line: This isn't just an Ozempic story. It's a playbook. And once you see how it works, you start seeing it everywhere.

🔔 New episodes every week — subscribe so you don't miss one.

🌐 Get involved at BustBigPharma.com

The Bust Big Pharma bus tour has now crossed more than 30 states, done hundreds of events, and collected enough petition signatures and engagement data to identify exactly which Senate races Big Pharma is most vulnerable in. The man who ran the ground operation for the 2025 tour knows exactly what that looked like from the inside.

In Episode 12, Rob sits down with Corey Stevens — former National Field Director for Americans for Pharma Reform — to talk about what happens when you take this issue directly to the American people. Town halls in rural New Mexico. 180 people showing up in a Texas border town. An elderly couple in Michigan asking for a bucket of stress ball remotes because they're fed up with pharma ads on their TV. Corey breaks down what he saw on the ground, what it told him about the 2026 map, and what he's telling his candidates right now.

In this episode:

• What it looks like when 200 people who agree on nothing else agree passionately on one thing: Big Pharma is ripping them off
• How the bus tour identified Bill Cassidy as a red flag — months before Louisiana voters sent him home
• Why Ken Paxton winning in Texas is not a coincidence — it's a pattern
• The difference between political capital and voter currency, and why pharma can't buy the second one
• What down-ballot candidates — city council, state rep, state senate — can start saying right now to make drug pricing a local issue
• Why pharma's DTC advertising jingles are targeting the next generation of patients — and what that means for families
• How engagement data from petition signatures, QR scans, and event turnout functions as a heat map for where the reform movement goes next
• The Michigan moment: one elderly couple, a bucket of stress ball remotes, and what it tells you about where this movement is headed

The bottom line: Big Pharma has $450 million in lobbying. AFPR has a bus, a petition, and a growing list of voters who are fed up. Corey Stevens spent 2025 crossing the country collecting proof that the second thing is more powerful than the first.

🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch